Imugene’s VAXINIA trial shows promising early results for solid tumours
Imugene Limited (ASX: IMU), a prominent player in the immuno-oncology field, has released an encouraging update on its Phase 1 MAST trial, which evaluates the safety and efficacy of the novel oncolytic virus, CF33-hNIS (VAXINIA), used both as monotherapy and in combination with pembrolizumab (KEYTRUDA). As the trial progresses, noteworthy outcomes are emerging, particularly in […]